Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00002224 | Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI) | PHASE3 | COMPLETED | 120 | — | — | Mar 1, 1999 | Mar 1, 1999 | Apr 25, 2011 | 24 | United States, Canada |
| Name | Type | Description |
|---|---|---|
| Nelfinavir mesylate | DRUG | - |
| Stavudine | DRUG | - |
| Didanosine | DRUG | - |
Inclusion Criteria You may be eligible for this study if you: * Are HIV-positive. * Are at least 18 years old. * Have a viral load of at least 5,000 copies/ml and a CD4 count of at least 100 cells/mm3. Exclusion Criteria You will not be eligible for this study if you: * Have received more than ...